Hadean Ventures

Gesynta Pharma AB is a clinical-stage pharmaceutical company based in Stockholm, Sweden, founded in 2017. The company focuses on developing compounds that inhibit the pro-inflammatory enzyme microsomal prostaglandin E synthase-1 (mPGES-1) to address chronic inflammatory conditions, particularly in cardiovascular diseases and cancer. Its most advanced drug candidate, vipoglanstat (GS-248), is being developed as a non-hormonal treatment for endometriosis, a painful condition affecting around 10 percent of women of reproductive age. Clinical studies have indicated that vipoglanstat significantly reduces endometriotic lesions and provides pain relief, with preparations underway for a phase II clinical trial. Additionally, Gesynta Pharma is advancing another candidate, GS-073, which is set to enter phase I clinical trials for a different inflammatory condition. The company's research is rooted in work from the Karolinska Institutet, and it aims to deliver safe and effective treatments for serious diseases.

SciRhom GmbH is a biotech company focused on the preclinical and early clinical development of novel biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Founded in 2016 through collaboration between academic and industry scientists with expertise in antibody development, SciRhom leverages extensive research and a network of specialists to advance its therapeutic offerings. The company develops therapeutic antibodies targeting iRhom2, a significant modulator of key pro-inflammatory signaling pathways, including TNF-alpha. This approach seeks to enhance treatment options for patients suffering from severe autoimmune conditions, particularly those affecting the skin and intestinal barriers.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

Alex Health AB, based in Stockholm, is an innovative AI and psychology startup dedicated to improving mental health through behavioral change. Founded in 2017, the company is currently developing a second-generation app aimed at helping one billion individuals overcome detrimental habits. Alex Therapeutics, its digital therapeutics division, focuses on enhancing clinician support for patients struggling with unwanted behaviors that negatively impact their health. Utilizing a proprietary AI platform, the company creates CE-marked software medical devices for various therapeutic areas, including obesity, breast cancer, and nicotine addiction. By combining psychology, design, and technology, Alex Health offers evidence-based digital interventions that provide personalized care and self-healthcare solutions, paving the way for more accessible healthcare. The company is located at Norrsken House in Stockholm.

Alex Health AB, based in Stockholm, is an innovative AI and psychology startup dedicated to improving mental health through behavioral change. Founded in 2017, the company is currently developing a second-generation app aimed at helping one billion individuals overcome detrimental habits. Alex Therapeutics, its digital therapeutics division, focuses on enhancing clinician support for patients struggling with unwanted behaviors that negatively impact their health. Utilizing a proprietary AI platform, the company creates CE-marked software medical devices for various therapeutic areas, including obesity, breast cancer, and nicotine addiction. By combining psychology, design, and technology, Alex Health offers evidence-based digital interventions that provide personalized care and self-healthcare solutions, paving the way for more accessible healthcare. The company is located at Norrsken House in Stockholm.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

Ribbon Biolabs GmbH, founded in 2018 and based in Vienna, Austria, specializes in the synthesis of long deoxyribonucleic acid (DNA) molecules. The company employs innovative techniques to produce DNA of unprecedented lengths, setting new standards in molecular biology. Its services cater to the diverse needs of synthetic biology, supporting researchers and companies in various applications, including genome construction, high-throughput library creation, and the development of DNA-based products and nanotechnology devices. By enabling the synthesis of long DNA sequences without economic or time constraints, Ribbon Biolabs aims to advance the next wave of biotechnologies and facilitate cutting-edge research in genetic solutions.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

Oncoinvent AS is a company focused on developing innovative cancer treatments by utilizing established physical and chemical principles in the application of novel materials. Their approach aims to enhance medical benefits while reducing safety concerns associated with these treatments. By creating pharmaceutical products specifically designed for the healthcare sector, Oncoinvent seeks to provide effective therapeutic options for cancer patients, contributing to improved patient outcomes in the field of oncology.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

CardioMech is a Norwegian company focused on developing therapeutic devices for structural heart disease, specifically aimed at providing a transcatheter alternative to traditional cardiac surgery. Founded in 2015 and headquartered in Trondheim, the company specializes in catheter-based technology that facilitates the placement of artificial chords for the mitral valve. This innovative approach allows surgeons to address severe symptomatic degenerative mitral regurgitation (DMR) caused by conditions such as prolapse or flail, without the need for open-heart surgery. By enabling minimally invasive procedures, CardioMech's devices offer new therapeutic options for patients suffering from moderate to severe mitral regurgitation, thereby improving treatment outcomes while reducing the risks associated with more invasive surgical methods.

Gesynta Pharma AB is a clinical-stage pharmaceutical company based in Stockholm, Sweden, founded in 2017. The company focuses on developing compounds that inhibit the pro-inflammatory enzyme microsomal prostaglandin E synthase-1 (mPGES-1) to address chronic inflammatory conditions, particularly in cardiovascular diseases and cancer. Its most advanced drug candidate, vipoglanstat (GS-248), is being developed as a non-hormonal treatment for endometriosis, a painful condition affecting around 10 percent of women of reproductive age. Clinical studies have indicated that vipoglanstat significantly reduces endometriotic lesions and provides pain relief, with preparations underway for a phase II clinical trial. Additionally, Gesynta Pharma is advancing another candidate, GS-073, which is set to enter phase I clinical trials for a different inflammatory condition. The company's research is rooted in work from the Karolinska Institutet, and it aims to deliver safe and effective treatments for serious diseases.

Oncoinvent AS is a company focused on developing innovative cancer treatments by utilizing established physical and chemical principles in the application of novel materials. Their approach aims to enhance medical benefits while reducing safety concerns associated with these treatments. By creating pharmaceutical products specifically designed for the healthcare sector, Oncoinvent seeks to provide effective therapeutic options for cancer patients, contributing to improved patient outcomes in the field of oncology.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

Abliva AB is a Swedish pharmaceutical company focused on the research and development of treatments for primary mitochondrial diseases, which are rare and severe conditions caused by dysfunctional mitochondria. The company's pipeline includes KL1333, currently in phase I clinical trials, and NV354, an energy replacement therapy that is preparing for clinical trials. KL1333 is noted for its role as a regulator of NAD+ and NADH, and has received orphan drug designation in both Europe and the United States. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injury. Established in 2000 and headquartered in Lund, Sweden, Abliva has formed collaborations with various institutions, enhancing its research capabilities and clinical development efforts.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Nisonic is a medical technology company focused on developing innovative products for the non-invasive diagnosis and monitoring of increased intracranial pressure (ICP). The company's advanced ultrasound technology utilizes an optimized transducer for transorbital imaging and employs machine-learning algorithms to provide automatic measurements and guidance for accurate probe positioning. This approach enables medical professionals in emergency departments, intensive care units, and critical care settings to detect ICP early and intervene effectively, thereby reducing the reliance on invasive methods that carry risks of complications and are limited to larger hospitals. By integrating their software with existing ultrasound devices, Nisonic aims to enhance the accessibility and cost-effectiveness of ICP monitoring, ultimately improving patient outcomes and lowering mortality and disability rates associated with elevated intracranial pressure.

Attgeno is a pharmaceutical company focused on developing treatments for acute, life-threatening conditions. The company specializes in nitric oxide-donating drugs that are designed to selectively target and reduce elevated blood pressure in the lungs. Their innovative drug utilizes nitric oxide-containing substances with distinct properties that facilitate the delivery of the medication directly to the lungs. By promoting the expansion of blood vessels in this area, Attgeno's treatment aims to effectively lower pulmonary pressure, thereby providing healthcare professionals with a valuable tool to manage critical health situations in their patients.